This article summarized the latest R&D progress of thioridazine hydrochloride, the Mechanism of Action for thioridazine hydrochloride, and the drug target R&D trends for thioridazine hydrochloride.

The N-Methyl-D-Aspartate (NMDA) receptor is a type of ionotropic glutamate receptor that plays a crucial role in excitatory synaptic transmission, plasticity, and excitotoxicity in the central nervous system, closely related to the body's memory, learning, and emotions.

This article summarized the latest R&D progress of tolfenamic acid, the Mechanism of Action for tolfenamic acid, and the drug target R&D trends for tolfenamic acid.

Arvinas Inc. recently reported positive results for its AR-targeting protein degraders, bavdegalutamide (ARV-110) and ARV-766, in Phase 1/2 trials for mCRPC treatment at ESMO.

This article summarized the latest R&D progress of taurolidine, the Mechanism of Action for taurolidine, and the drug target R&D trends for taurolidine.

In mapping the evolutionary trajectory of the patenting landscape pertaining to Mirvetuximab Soravtansine, it is critical to analyze the strategic approach of the top 10 assignees. There is also a dynamic shift in the competition blueprint that is dictated by the progression of time.

This article summarized the latest R&D progress of tamibarotene, the Mechanism of Action for tamibarotene, and the drug target R&D trends for tamibarotene.

Immutep recently introduced its novel LAG-3 immunotherapy, Eftilagimod Alpha (Efti), for cancer and autoimmune disease treatment at the 2023 ESMO meeting. It presented positive data from two trials for Efti with pembrolizumab ± double chemotherapy as first-line NSCLC treatments.

This article summarized the latest R&D progress of sunvozertinib, the Mechanism of Action for sunvozertinib, and the drug target R&D trends for sunvozertinib.

p53 inhibitors interfere with the normal function of the p53 protein and are primarily used as research tools to study the biological effects of p53 inactivation.

This article summarized the latest R&D progress of sulfadiazine/trimethoprim, the Mechanism of Action for sulfadiazine/trimethoprim, and the drug target R&D trends for sulfadiazine/trimethoprim.

Inxmed Co. announced that the significant clinical research results of its independently developed core product, Ifebemtinib (IN10018), the world's first small molecule FAK inhibitor.